The auto-injecting blood sugar trackers will be distributed to more than 100,000 people with diabetes in England under the NHS scheme.
A new wearable monitor resembles an artificial pancreas that pumps insulin into the body when needed.
Hybrid closed-loop monitors will help patients manage blood glucose levels without the need for manual monitoring of blood glucose levels.
That means people with type 1 diabetes don’t need continuous glucose monitors or finger prick tests to check their levels — nor do they need daily insulin injections to treat the disease.
The National Institute for Health and Care Excellence (NICE) said an estimated 105,000 people in England would have access to the technology, at a cost of around £5,700 a year.
Diabetes UK said the new device could “significantly reduce the emotional burden on people living with diabetes”.
Policy manager Nikki Joule said: “Type 1 diabetes takes a huge mental toll, with people needing to manually calculate how much insulin they need regularly throughout the day.
“By automating these calculations, the hybrid closed-loop technique could greatly reduce the emotional burden on diabetic patients.”
People who are currently unable to manage their symptoms should first get the technology on a temporary basis, according to NICE guidance.
Pregnant women should also be eligible, it added.
NICE’s interim director of medical technology said: “Some people with type 1 diabetes are having trouble managing their disease, even though they are doing everything their diabetes team asks them to.
“Unless cured, this technology is the best intervention to help them manage their diabetes.
Read more Sky News
Ultimate homework cheating? How Teachers Face ChatGPT
How cancer vaccines work and everything you need to know about the government’s BioNTech deal
“We look forward to working with NHS England and industry to ensure a cost-effective price that is fair to the taxpayer can be reached.”
Professor Partha Kar, National Professional Adviser for NHS England, added: “This technology has been shown to best manage type 1 diabetes and should make issues such as amputations, blindness and kidney problems a possible thing of the past.
“We’ve seen fantastic results from the real-world trials that have taken place, thanks to NICE’s review of the evidence and subsequent conclusions.
“This technology brings enormous quality of life to those who use it.”